The 5th Annual Tumor Models Boston provided attendees with the latest preclinical & clinical insights to advance oncology pipelines. The event showcased the latest advancements in the application of preclinical models to enhance the translation of cancer therapies from animal to patient.
The conference looked at how the industry have been selecting & characterizing in vitro models, ex vivo assays, syngeneic models, PDX, humanized mice models to optimize their application in preclinical and translational studies for targeted therapies, cancer immunotherapies and combination therapies. Also highlighted were the valuable clinical lessons that are helping to transform preclinical research through reverse translation and to extract more value from preclinical models to enhance preclinical and translational decision making into the clinic.
Horizon's Jochen Hartner gave a talk at Tumor Models entitled 'Highly Characterized Patient-Derived Xenograft Collections for Preclinical Studies'. This was at 10:40am on Wednesday 19 July.
Tumor Models Boston 2017 addressed the preclinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between preclinical and clinical studies. The event looked at progressing future cancer treatments into the clinic more effectively and faster.